JUN 2 4 2005

06-27-05

JEW/AF

TRADE MENDMENT TRANSMITTAL LETTER					Docket No. 03818/100L652-US1
Application No. 10/616,046		Filing Date July 8, 2003		Examiner E. Peselev	Art Unit 1623
Applicant(s): Mlac	den Mercep et	al.			
				ARRIERS FOR STE D ANTIVIRAL ACTI	EROID/NONSTEROID VE MOLECULES
		THE COMMI			
Transmitted hereversely. The fee has been				• •	
110 100 1100 20011			S AS AMENI		
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	60	- 60 =	0	х	0
Independent Claims	26	- 26 =	0	x	0
Multiple Depend	ent Claims (ch	eck if applicabl	e)		
Other fee (please specify): Extension for response within second month					450.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					450.00
x Large Entity				Small Entity	
	I fee is require				
	ge Deposit Acc copy of this she			n the amount of \$ _	•
X A check in the amount of \$ 450.00 to cover the filing fee is enclosed.					
Payment by	credit card. Fo	orm PTO-2038	is attached.		
	is hereby auth I below. A dup			Deposit Account Nenclosed.	o. <u>04-0100</u>
x Credit ar	ny overpaymer	nt.			
x Charge a	any additional fili	ing or applicatio	n processing	fees required under 3	37 CFR 1.16 and 1.17.
Lydia Gayle Ols Attorney Reg. N				Dated:	June 24, 2005
DARBY & DAR P.O. Box 5257 New York, New (212) 527-7770	BY P.C. York 10150-5	5257			



Docket No.: 03818/100L652-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mladen Mercep et al.

Application No.: 10/616,046

Filed: July 8, 2003 Art Unit: 1623

For: NOVEL COMPOUNDS, COMPOSITIONS AS

CARRIERS FOR STEROID/NONSTEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES Examiner: E. Peselev

AMENDMENT AFTER FINAL ACTION (37 C.F.R. SECTION 1.116)

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

The undersigned would like to thank the Examiner for her comment during an Interview on June 24, 2005. As discussed, Applicants have amended claim 1. Therefore this amendment and comment are in response to the Office Action dated January 25, 2005 finally rejecting claims 1, 2 and 9-52, and in response to the Advisory Action dated April 5, 2005, rejecting claims 1 and 37-53 and allowing claims 2, 9-36 and 54-66. A petition for extension of time and a check for the required fee are enclosed to extend the deadline for response to June 25, 2005. Please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 53 of this paper.